Exelixis (NASDAQ:EXEL) will report earnings after markets close on Tuesday, May 7th. Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The Company is building a portfolio of compounds it believes could become pharmaceutical products. Exelixis has strategic alliances with pharmaceutical and biotechnology companies.
Here is your Cheat Sheet to Exelixis Earnings:
Earnings Expectations: Analysts expect earnings of $-0.28 per share on revenues of $5.33 million.
Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.27 to a loss $0.3. For the current year, the average estimate is a loss of $1.24, which is worse than the estimate ninety days ago.
Here’s how Exelixis has been performing on an annual basis:
|Revenue ($) in millions||117.86||151.76||185.04||289.64||47.45|
|Diluted EPS ($)||-1.54||-1.26||-0.85||0.58||-0.92|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Dec. 31, 2011||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||93.31||18.51||7.81||13.31||7.81|
|Diluted EPS ($)||0.3460||-0.18||-0.25||-0.20||-0.2843|
Exelixis has beat analyst estimates 2 times in the past four quarters. This is not consistent enough to get bullish yet.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)